Kura Oncology, Inc. KURA
10.76
(0.10)
(0.92%)
as of 25 Sep
- Market cap
- $977.7M
- P/E
- 0.0×
Follow KURA
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (167.71%) | (124.74%) | (94.82%) | (65.10%) |
+8 more TTM periods Free account |
|
| (46.73%) | (42.19%) | (37.19%) | (38.45%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(66.12%) | (55.59%) | (46.48%) | (42.80%) | |
Average Days of Receivables |
44.65 | 47.63 | 47.62 | 0.00 | |
Free Cash Flow per Share |
(1.32) | (0.95) | (0.81) | 0.95 | |
Free Cash Flow |
(117.43) | (84.46) | (70.70) | 83.11 | |
Capital Expenditures |
(5.67) | (6.47) | (6.64) | (4.69) | |
Piotroski F-Score |
3.00 | 3.00 | 4.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(19.36%) | (11.17%) | (7.53%) | 10.95% | |
Accounts Receivable Turnover |
11.02 | 2.47 | 12.42 | 0.00 | |
Accounts Payable Turnover |
0.03 | 0.03 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | 0.00 | — | — | |
Average Days of Payables |
934.78 | 2,865.88 | 0.00 | 0.00 | |
Days of Inventory on Hand |
971.12 | 343.03 | 0.00 | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
335.99% | 363.44% | 372.06% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
175.18% | 179.65% | 177.80% | 0.00% | |
Share Based Compensation of Revenue |
50.43% | 52.60% | 54.99% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.38 | 0.26 | 0.23 | (0.40) | |
Depreciation/Fixed assets |
(0.48) | (0.73) | (0.95) | (1.24) | |
Capex/Depreciation |
1.55 | 1.16 | 0.89 | 0.51 | |
Revenue per Share |
0.87 | 0.81 | 0.77 | 0.00 | |
Operating CF per Share |
(1.26) | (0.88) | (0.73) | 1.00 | |
Capex per Share |
(0.06) | (0.07) | (0.08) | (0.05) | |
Capex to Sales |
0.07 | 0.09 | 0.10 | 0.00 | |
Net Profit Margin |
(384.30%) | (411.19%) | (412.95%) | 0.00% |
Columns are period end dates